Guggenheim Upgrades Amicus Therapeutics to Buy, Announces $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay upgrades Amicus Therapeutics (FOLD) from Neutral to Buy and sets a $13 price target.
May 14, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics was upgraded by Guggenheim from Neutral to Buy with a new price target of $13, indicating a positive outlook on the stock.
Upgrades by reputable analysts like Guggenheim often lead to short-term positive momentum in the stock price as market perception shifts. The new price target of $13 suggests a significant upside potential from current levels, which could attract more investors to the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100